Advanced Solid Tumors
Advanced Solid Tumors
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
20
Clinical Trials
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06586957 / NKT3964-101
A PHASE 1, FIRST-IN-human, open-label study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of the novel oral CDK2 DEGRADER NKT3964 in adults with advanced/metastatic solid tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06778863 / CLSP-1025-101
A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients with Solid Tumors that harbor the TP53-R175H Mutation
Learn More
Advanced Solid Tumors
Phase I/II
Enrolling
nct/study# NCT04145622 / DS7300-A-J101
Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects With Advanced Solid Malignant Tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05836324 / INCA33890-101
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06792552 / SIM0505-101
A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS
Learn More
Advanced Solid Tumors
Phase I/II
Enrolling
nct/study# NCT05584670 / TCD17620
A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy in adults with advanced solid tumors
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.